GlassScriptPhysician profile
Jamie Roberts
NPI 1235577537
$10,730.61
in general payments reported to CMS, 2019-2025
27 companies · $2,812 in 2025
The $2,812 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,513 · 2022: $1,988 · 2023: $1,892 · 2024: $2,525 · 2025: $2,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,123 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,122.52 |
| Education | $106.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,723.27 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,596.45 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,074.38 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $819.83 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $714.12 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $646.40 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $583.84 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Pfizer INC. | $418.10 | 2021-2024 | |
| Leo Pharma INC. | $412.61 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $365.37 | 2023-2025 | Zoryve |
| Ucb, INC. | $280.20 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $267.03 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $261.96 | 2023-2025 | Otezla |
| Mayne Pharma Commercial LLC | $220.33 | 2022-2025 | |
| Almirall LLC | $209.52 | 2022-2025 | Seysara |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $199.19 | 2022-2025 | Nemluvio |
| Incyte Corporation | $181.92 | 2021-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $180.67 | 2022 | |
| Genentech USA, INC. | $151.36 | 2021-2022 | |
| Epi Health, LLC | $98.13 | 2022 | |
| Mallinckrodt Hospital Products INC. | $89.81 | 2024-2025 | Acthar |
| Organon LLC | $61.33 | 2025 | Vtama |
| Nabriva Therapeutics, Plc | $47.52 | 2021-2022 | |
| Dermavant Sciences, INC. | $45.78 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.42 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Biofrontera INC. | $24.73 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Laborie Medical Technologies Corp. | $17.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.